Detalhe da pesquisa
1.
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Diabetes Obes Metab
; 21(4): 812-821, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30447037
2.
Arginine is preferred to glucagon for stimulation testing of ß-cell function.
Am J Physiol Endocrinol Metab
; 307(8): E720-7, 2014 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25159323
3.
Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
J Clin Pharmacol
; 2024 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38563070
4.
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
Clin Pharmacol
; 15: 9-19, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36880014
5.
Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.
Int J Clin Pharmacol Ther
; 50(8): 584-94, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22578199
6.
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
BMJ Open Respir Res
; 9(1)2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35058236
7.
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Clin Pharmacol Drug Dev
; 11(12): 1394-1404, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36256505
8.
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Adv Ther
; 37(12): 4944-4958, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33025342
9.
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Adv Ther
; 37(10): 4381-4395, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32857315
10.
Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.
Cardiovasc Res
; 115(3): 669-677, 2019 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30184110
11.
Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function.
Contemp Clin Trials Commun
; 10: 94-99, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30023442
12.
Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with ß Cell Function.
Metab Syndr Relat Disord
; 16(8): 406-415, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30117761
13.
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Cancer Chemother Pharmacol
; 57(4): 401-11, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16322991
14.
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Cancer Chemother Pharmacol
; 57(4): 412-26, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16322990
15.
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Cancer Chemother Pharmacol
; 57(4): 427-35, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16322992
16.
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
PLoS One
; 9(9): e110069, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25268802
17.
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
PLoS One
; 9(8): e105638, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25166023
18.
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
J Clin Endocrinol Metab
; 98(5): E867-71, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23585665
19.
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
Diabetes Care
; 36(8): 2154-61, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23412078
20.
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
Eur J Heart Fail
; 15(6): 679-89, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23471413